LONDON and CAMBRIDGE, MA--(MARKET WIRE)--Oct 28, 2008 --
London, UK, and Cambridge, MA: 28 October 2008: Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that Eric Dodd has been appointed as Chief Financial Officer with effect from November 3rd 2008 and that he will join the Antisoma Board as an Executive Director.

Mr Dodd, 39, has extensive experience in technology businesses. He was previously Group Finance Director at Morse plc, a consulting, IT services and technology company. Before joining Morse in 2005, he held management positions at a number of companies, including GlaxoSmithKline, where he worked in the UK pharmaceuticals business. Mr Dodd qualified as an accountant with Deloitte and holds an MBA from London Business School.

Raymond Spencer, Antisoma's current Chief Financial Officer, will become Corporate Development Director and will remain on the Board.

Barry Price, Chairman of Antisoma, said: "Eric brings significant new experience to Antisoma as the Company makes a transition towards involvement in selling its own products. We welcome him to the team."

There are no other disclosures relating to Mr Dodd under Listing Rule LR 9.6.13.

Background on Antisoma

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The Company has operations in the UK and the US. Please visit www.antisoma.com for further information about Antisoma.

---END OF MESSAGE---

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.

     Enquiries:
     Glyn Edwards, CEO
     Daniel Elger, Director of Communications
     +44 (0)20 3249 2100
     Antisoma plc
      
     Mark Court/Lisa Baderoon/Rebecca Skye
     +44 (0)20 7466 5000
     Dietrich
     Buchanan Communications
      
     Seth Lewis
     +1 617-583-1308
     The Trout Group